N-Terminal Pro-B-Type Natriuretic Peptide in Overweight and Obese Patients With and Without Diabetes: An Analysis Based on Body Mass Index and Left Ventricular Geometry by Park, Seung Jei et al.
 
 
  538
ORIGINAL ARTICLE 
DOI 10.4070 / kcj.2009.39.12.538 
Print ISSN 1738-5520 / On-line ISSN 1738-5555
Copyright ⓒ 2009 The Korean Society of Cardiology
Open Access   
N-Terminal Pro-B-Type Natriuretic Peptide in Overweight and   
Obese Patients With and Without Diabetes: An Analysis Based 
on Body Mass Index and Left Ventricular Geometry 
 
Seung Jei Park, MD, Kyoung Im Cho, MD, Sun Jae Jung, Sung Won Choi, MD,   
Jae Won Choi, MD, Dong Won Lee, MD, Hyeon Gook Lee, MD and Tae Ik Kim, MD 
Division of Cardiology, Maryknoll Medical Center, Busan, Korea 
 
ABSTRACT 
Background and Objectives: Several recent studies have shown that there is an inverse relationship between 
plasma B-type natriuretic peptide (BNP) and body mass index (BMI) in subjects with and without heart failure. 
Obesity frequently coexists with diabetes, so it is important to consider the relationship between diabetes and 
natriuretic peptide levels. We evaluated the influence of diabetes on the correlation of BNP and BMI. Subjects 
and Methods: We examined 933 patients with chest pain and/or dyspnea undergoing cardiac catheterization 
between Feb. 2006 and Nov. 2007 in the Maryknoll cardiac center who had creatinine levels <2.0 mg/dL and 
normal systolic heart function. BMI was checked, transthoracic echocardiography was performed, and amino-
terminal pro-brain natriuretic peptide (NT-proBNP) was sampled at the start of each case. Results: In 733 non-
diabetic patients, mean plasma NT-proBNP levels of non obese individuals (BMI <23 kg/m
2), overweight indi-
viduals (23≤ BMI <25 kg/m
2), and obese individuals (BMI ≥25 kg/m
2) showed a significant negative correlation 
with increasing BMI (856.39±237.3 pg/mL, 601.69±159.6 pg/mL, 289.62±164.9 pg/mL, respectively, p<0.0001). 
However, in 200 diabetic patients, the correlation between BMI and NT-proBNP was not significant (r=-0.21, 
p=0.19), and NT-proBNP did not correlate with mitral E/Ea in obese diabetic patients (r=0.14, p=0.56). NT-
proBNP was significantly correlated with mitral E/Ea in the non-obese (r=0.24, p=0.008) and non diabetic 
(r=0.32, p=0.003) groups. Left ventricular (LV) mass index was significantly correlated with NT-proBNP in all 
BMI groups (r=0.61, p<0.001), and patients with concentric cardiac hypertrophy showed the highest NT-proBNP 
levels.  Conclusion: The present study demonstrates that obese patients have reduced concentrations of NT-
proBNP compared to non obese patients despite having higher LV filling pressures. However, NT-proBNP is not 
suppressed in obese patients with diabetes. This suggests that factors other than cardiac status affect NT-proBNP 
concentrations. (Korean Circ J 2009;39:538-544)   
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Introduction 
 
Natriuretic peptides are frequently used in diagnosing 
and monitoring patients with congestive heart failure 
(CHF). B-Type natriuretic peptide (BNP) and aminoter-
minal pro-brain natriuretic peptide (NT-proBNP) are 
believed to correlate with the severity of heart failure 
symptoms and objective measures of heart function.
1-3) 
The NT-proBNP levels are affected by demographic va-
riables such as age, gender, and ethnicity, and clinical 
characteristics such as hypertension, atrial fibrillation, 
and renal function.
4-6) Elevated body mass index (BMI) 
and obesity have been associated with hypertension, in-
sulin resistance and dyslipidemia, and contribute to de-
leterious hemodynamic and morphologic cardiovascular 
changes.
7-9) Recent studies demonstrated that obesity is 
associated with decreased levels of NT-proBNP and rais-
ed concerns about the diagnostic and prognostic validity 
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of natriuretic peptides in obese patients.
10)11) NT-proBNP 
has been shown to be increased in patients with dia-
betes mellitus (DM), even in the absence of structural 
heart disease, and obesity frequently coexists with dia-
betes. Hence, variety factors should be considered to be 
associated with the interindividual variability of plasma 
NT-proBNP levels in the diagnosis and management of 
heart failure patients. So, our study aimed to further 
explore the association between elevated BMI and NT-
proBNP in diabetes and the relationship of echocardio-
graphic indexes of increased left ventricular (LV) filling 
pressure, LV geometry and atherosclerosis as measured 
by common carotid intima-media thickness (CCIMT). 
 
Subjects and Methods 
 
Patients with chest pain and/or dyspnea who under-
went cardiac catheterization from Feb. 2006 to Nov. 2007 
in Maryknoll cardiac center were enrolled. Subjects with 
atrial fibrillation or other significant cardiac arrhythmia 
and acute myocardial infarction at the time of clinical 
assessment were excluded. Other exclusion criteria in-
cluded patients who did not provide written consent and 
patients with regional wall motion abnormalities; symp-
tomatic or asymptomatic LV systolic dysfunction (ejec-
tion fraction <50%); significant valvular disease (mo-
derate or severe valvular dysfunction); and neoplastic, 
hepatic, and renal dysfunction. At the time of enroll-
ment, data were collected on each subject, including de-
mographics, physical examination, results of unblinded 
laboratory testing, and self-reported medical history and 
active symptoms. Severity of dyspnea was based on New 
York Heart Association criteria. Diabetes mellitus (DM) 
was diagnosed if fasting plasma glucose was ≥126 mg/ 
dL or if participants were taking insulin or oral hypogly-
cemic medications. Patients without DM were defined 
as non DM. Patients were divided into body mass index 
(BMI) >25 g/m
2 (obese), 23 to 25 (overweight), and <23 
kg/m
2 (non obese) according to the guideline of the 
Korean society for the study of obesity. Significant co-
ronary artery disease was considered if the stenosis was 
above 50% from the quantitative angiography. 
 
Echocardiographic evaluation 
Measurements of left atrial (LA) dimension, left ven-
tricular (LV) dimension, LV end diastolic and systolic 
volume, interventricular septal thickness (IVSd), LV pos-
terior wall thickness (LVPWTd) and ejection fraction 
were performed from 2-dimensionally targeted M-mode 
tracings according to the recommendations of the Ame-
rican Society of Echocardiography (ASE). LV mass was 
calculated by the corrected ASE cube formula and in-
dexed for body surface area to obtain the LV mass index. 
The relative posterior wall thickness (RWT) was mea-
sured at end diastole as the ratio between the double of 
posterior wall thickness to the LV diastolic cavity dia-
meter. LV hypertrophy (LVH) was defined as increased 
LV mass index >104 g/m
2 in women and >116 g/m
2 in 
men.
12) Concentric hypertrophy was defined as LVH with 
increased RWT (>0.43). Concentric LV remodeling was 
defined as increased RWT with normal LV mass index. 
Eccentric hypertrophy was defined as LVH without in-
creased RWT. Transmitral peak early (E), atrial (A) dia-
stolic velocities were measured in the apical 4-chamber 
view with the sampling volume positioned at the tips of 
the mitral valve. The isovolumic relaxation time (IRT), 
isovolumic contraction time (ICT) and total ejection time 
was measured at the apical 5-chamber view with the 
sampling volume positioned between the mitral valve 
and the LV outflow tract as the time taken from the 
closure of the aortic valve to the opening of the mitral 
valve. The index of combined LV systolic and diastolic 
function (the sum of ICT and IRT divided by ejection 
time) was calculated which described by Tei et al.
13) 
Tissue Doppler measurements were obtained from the 
apical 4-chamber view, and the sampling volume was 
placed at the medial (septal) and lateral corners of the 
mitral annulus. Early (Ea) diastolic mitral annular velo-
cities were taken as the average of 3 measurements at 
each side of the mitral annulus. All echocardiograms 
were performed and analyzed by one observer.   
 
Measurement of common carotid IMT 
Ultrasonography of the carotid arteries was performed 
with a 10-MHz transducer (System Five, General Elec-
tronics Corp., Horten, Norway). When an optimal lon-
gitudinal image of the common carotid artery was ob-
tained, it was frozen on the R wave of the electrocardio-
gram, and 5 measurements were taken from the far wall 
of the distal 1 cm of the common carotid artery. This 
was repeated on the other side, and the average mea-
surement from the 2 sides was taken as the CCIMT (a 
surrogate index for atherosclerosis). Plaques or focal 
protrusions were avoided. Measurements were taken at 
the time of examination before laboratory analysis.   
 
Measurement of plasma NT-proBNP levels 
The NT-proBNP level was analyzed at the time of cli-
nical assessment. For each NT-proBNP measurement, 5 
mL of whole blood was collected into tubes containing 
ethylene diamine tetraacetic acid (EDTA) and measured 
using the Elecycs 2010 platform (Roche Diagnostics, 
USA). 
 
Statistical analysis 
All data were presented as means±standard devia-
tion and analyzed using standard statistical software 
{Statistical Package for Social Science (SPSS) version 13.0, 
Chicago, IL, USA}. Because of the large range in NT-
proBNP, analysis and results using a semilogarithmic  
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scale is also reported. Continuous variables among the 
DM and the non DM group were analyzed by one-way 
ANOVA and variables between the two groups were 
compared by t-test. Discontinuous variables were com-
pared by Chi-square test. Correlations were obtained us-
ing Pearson’s method. Multivariate stepwise logistic re-
gression analysis was performed to assess the relation-
ship between the predictor variables such as age, gender, 
BMI, NYHA class, hypertension, diabetes mellitus, me-
dications, hemodynamic and echocardiographic indexes, 
and creatinine. A p<0.05 was considered statistically 
significant. 
 
Results 
 
The clinical characteristics of the study population 
Baseline characteristics of the overall patient popula-
tion are listed in Table 1. Among 933 patients, 733 were 
patients without DM {obese (n=287, 39.2%), over-
weight patients (n=216, 29.5%), and non obese (n=230, 
31.4%)} and 200 were DM patients {obese (n=91, 
45.5%), overweight patients (n=55, 27.5%), and non 
obese (n=54, 27%)}. The mean age was 60.8±10.39 
years in DM patients and 64.6±8.75 years in non-DM 
patients. Subjects with DM tended to be older and had 
a higher body mass index than non-diabetes groups but 
had a similar distribution of gender. There was no sig-
nificant difference between the DM and non-DM groups 
in cholesterol, systolic blood pressure, diastolic blood 
pressure, BUN, creatinine, and C-reactive protein. Ho-
wever, mean plasma NT-proBNP levels were significantly 
higher in DM patients than non-DM patients (913.28
±2720.58 and 559.42±1652 pg/mL, p=0.006) (Table 
1). Coronary artery stenosis lesion length (p=0.039), 
stent length (p=0.024), coronary artery adventitial dia-
meter (p=0.034), and mean CCIMT (p=0.016) were sig-
nificant higher in DM patients than non-DM patients 
(Table 2). In non DM patients, CCIMT was significantly 
higher in patients with significant coronary artery di-
sease than patients with minimal coronary artery di-
sease (1.23±0.568 mm vs. 1.00±0.304 mm, p=0.005). 
However, CCIMT showed no significant correlation with 
mean plasma NT-proBNP level (Table 3).  
Table 1. Comparisons of clinical variables between DM and non-
DM groups 
  Non-DM  
(n=733) 
DM  
(n=200)  p 
Age (years)  060.3±11.12 64.8±9.25 0.054
Male (%)  62.3  46.7  0.065
Body weight (kg)  58.3±9.80 62.5±7.90 0.012
Body mass index (g/m
2) 23.78±4.560 25.43±3.380 0.005
Total cholesterol (mg/dL)  179.6±50.22 173.0±40.92 0.687
Systolic BP (mmHg)  127.2±20.96 129.4±20.23 0.544
Diastolic BP (mmHg)  079.2±13.42  077.7±11.56 0.436
NT-pro BNP (pg/mL)  559.42±16520 913.28±2720.58 0.006
BUN (mg/dL)  018.9±21.64  022.5±17.84 0.069
Creatine (mg/dL)  01.0±0.84  01.2±0.96 0.062
Fasting glucose (mg/dL)  101±11.9  0 127±14.2 0.001
cTnT (ng/mL)  0.02±0.03 0.04±0.05 0.085
hsCRP (mg/L)  008.3±25.11  007.2±16.21 0.233
All values are described in mean±SD. DM: diabetes mellitus, BP:
blood pressure, NT-pro BNP: amino-terminal pro-brain natriuretic
peptide, BUN: blood urea nitrogen, cTnT: cardiac specific troponin,
hsCRP: high sensitivity C-reactive protein   
Table 2. Comparisons of coronary angiographic and carotid ul-
trasonographic variables between DM and non-DM groups 
  Non-DM  
(n=733) 
DM  
(n=200)  p
Lesion length (mm)  4.96±9.80  08.02±11.67 0.039
Stent length (mm)  05.64±11.22  09.48±13.48 0.024
Adventitial diameter (mm) 7.95±1.05 8.35±0.64 0.034
CCIMT (mm)  01.15±0.540  01.36±0.700 0.016
All values are described in mean±SD. DM: diabetes mellitus, CC-
IMT: common carotid intima-media thickness 
 
Table 4. Comparisons of echocardiographic variables between 
the DM and the non-DM group 
  Non-DM 
(n=733) 
DM 
(n=200)  p
LV EF (%)  063.3±6.71  061.9±8.69 0.087
RWT  04.37±0.55  04.49±0.67 0.065
LV mass index (g/cm
2)1 2 1 . 1 8 ±37.99 129.82±27.83 0.012
LA diameter (cm)  04.07±0.45 4.27±0.45 0.005
E (cm/sec)  0 63.72±15.47  065.36±17.48 0.687
A (cm/sec)  0 79.63±16.14  086.41±17.86 0.544
E/Ea  07.35±2.65  08.61±2.78 0.005
Tei index  00.30±0.20 0.34±0.19 0.006
All values are described in mean±SD. LV: left atrium, DM: dia-
betes mellitus, EF: ejection fraction, RWT: relative wall thickness, 
LAD: left atrial dimension, E: peak early velocity, A: peak atrial ve-
locity, Ea: Early diastolic mitral annular velocity 
Table 3. Correlation analysis of variables with plasma NT-proBNP
between the DM and the non-DM group 
Univariate 
Variable 
r  p   
Multivariate
p 
Patients with non DM 
Age 0.18  0.270 0.340 
Body mass index  -0.73- 0.005  0.002 
LV mass index  0.65  0.001  0.003 
CC-IMT 0.04  0.650 0.350 
E/Ea 0.32  0.002  0.003 
Patients with DM 
Age 0.17  0.220 0.450 
Body mass index  -0.21- 0.190 0.230 
LV mass index  0.57  0.020 0.030 
CC-IMT 0.29  0.080 0.320 
E/Ea 0.14  0.560 0.410 
DM: diabetes mellitus, NT-proBNP: aminoterminal pro-brain na-
triuretic peptide, E: peak early velocity, CC-IMT: common ca-
rotid intima-media thickness, Ea: early diastolic mitral annular ve-
locity 
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The correlation between plasma BNP level and 
echocardiographic findings   
There was no significant difference between the DM 
and non-DM groups in LV ejection fraction, relative 
wall thickness, mitral E and A velocity. However, LV 
mass index, LA diameter, E/Ea and Tei index were 
significantly higher in DM patients than non-DM pa-
tients (Table 4). Plasma NT-proBNP values did not cor-
relate with LV filling pressure represented by mitral 
E/Ea in obese diabetic patients (r=0.14, p=0.56). How-
ever, NT-proBNP was significantly correlated with this 
variable in the non obese (r=0.24, p=0.008) and non-
DM patients (r=0.32, p=0.005). The significant cor-
relation of NT-proBNP and LV mass index was observ-
ed in univariate linear regression analysis (r=0.65, p= 
0.001) and patients with concentric hypertrophy showed 
the highest NT-proBNP levels (Fig. 1). Even after ad-
justing for age, gender, diabetes, creatinine, ejection frac-
tion and E/Ea in multivariate linear regression analysis, 
LV mass index was significantly associated with NT-
proBNP (r=0.57, p=0.03) (Table 3). 
 
The correlation between plasma BNP level and 
BMI 
In 733 non-DM patients, plasma NT-proBNP levels 
were significantly lower in obese (289.62±164.9 pg/mL) 
and overweight patients (601.69±159.6 pg/mL) com-
pared with non obese patients (856.39±237.3 pg/mL) 
Table 6. Comparisons of variables in the DM group according to the body mass index
  DM   
 
Non obese (n=54)  Overweight (n=55)  Obese (n=91) 
p
NT-proBNP (pg/mL)  963.19±223.7 1450.15±457.3 658.05±147.1 0.320
Log NT-proBNP (pg/mL)  05.52±1.97  005.36±2.41     5.13±1.74 0.650
Significant CAD (%)  63% (n=34) 53%  (n=29) 54%  (n=49) 0.120
NYHA class >II 54%  (n=29) 47%  (n=26) 44%  (n=40) 0.230
LV mass index (g/cm
3) 127.22±24.66  0129.93±26.36   133.11±34.85 0.120
RWT  00.43±0.06  0 0.43±0.51   0.43±0.54 0.320
E velocity  068.26±15.93  0 66.92±17.89     65.36±17.47 0.150
A velocity  089.63±19.34  0 86.79±15.89     85.02±14.38 0.500
E/Ea  07.48±2.32  0 8.45±2.56     9.92±2.45 0.260
Tei index  00.28±0.22  0 0.31±0.15*         0.38±0.22*
† 0.049
All values are described in mean±SD. DM: diabetes mellitus, NT-proBNP: amino-terminal pro-brain natriuretic peptide, CAD: coronary 
artery disease, NYHA: New York Heart Association, LV: left ventricle, RWT: relative wall thickness, E: peak early velocity, A: peak atrial 
velocity, Ea: early diastolic mitral annular velocity. *p<0.05 vs. non obese, †p<0.05 vs. overweight   
Table 5. Comparisons of variables in the non-DM group according to the body mass index
    Non-DM   
  Non-obese (n=230)  Overweight (n=216)  Obese (n=287) 
p
NT-proBNP (pg/mL)  856.39±237.3 601.69±159.6*  0 289.62±164.9*
† 0.002
Log NT-proBNP (pg/mL)  05.03±1.84  04.67±1.71*  0 4.32±1.58*
† 0.028
Significant CAD (%)  41% (n=94) 47%  (n=101) 43%  (n=122) 0.580
NYHA class >II 33%  (n=75) 38%  (n=82)1 32%  (n=93)1 0.770
LV mass index (g/cm
2)  0 121.99±53.95 124.08±27.58*  0127.61±27.93*
† 0.010
RWT  00.43±0.06 0.43±0.51 0.43±0.54 0.560
E (cm/sec)  064.39±15.18 63.85±15.28 62.70±14.69 0.690
A (cm/sec)  0 78.17±15.79 81.28±16.68 82.32±16.28 0.540
E/Ea  05.38±2.32  07.35±3.24*  0 9.32±2.38*
† 0.040
Tei index  00.27±0.20 0.29±0.20 0.31±0.20 0.180
All values are described in mean±SD. DM: diabetes mellitus, NT-proBNP: amino-terminal pro-brain natriuretic peptide, CAD: coronary artery 
disease, NYHA: New York Heart Association, LV: left ventricle, RWT: relative wall thickness, E: peak early velocity, A: peak atrial velocity, 
Ea: early diastolic mitral annular velocity. *p<0.05 vs. non obese, †p<0.05 vs. overweight 
 
Fig. 1. Comparisons of NT-proBNP level according to the left ven-
tricular geometry in the DM and non-DM group. DM: diabetes 
mellitus, NT-pro BNP: aminoterminal pro-brain natriuretic peptide,
CR: concentric remodeling, EH: eccentric hypertrophy, CH: con-
centric hypertrophy. 
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(p<0001) despite similar significant coronary artery di-
sease and severity of dyspnea (Table 5). However, in 200 
DM patients, plasma NT-proBNP levels was 963.19±
223.7 pg/mL, 1450.15±457.3 pg/mL, 658.05±147.1 
pg/mL, respectively, which showed no significant ne-
gative correlation between BMI and NT-proBNP (r= 
-0.21, p=0.19) (Table 3 and 6) Drop-line charts of log-
transformed mean plasma NT-proBNP levels (dependent 
variable) against BMI (independent) according to pre-
sence of significant coronary disease are shown in Fig. 2. 
Mean log NT-proBNP levels among patients with signi-
ficant coronary artery disease decrease with increasing 
obesity, which is statistically significant in non-DM pa-
tients (5.29±1.62, 4.77±1.65, 4.53±1.43, p=0.002). 
 
Discussion 
 
In recent years, natriuretic peptides have been gaining 
widespread popularity as sensitive and specific markers 
for the LV failure. BNP is principally produced in the     
ventricles as prohormone pre-proBNP, which is then 
enzymatically cleaved into the biologically active BNP 
(32 amino acids in length) and the biologically inactive 
NT-proBNP (76 amino acids in length).
14) It is found 
mainly in the cardiac ventricles, and its release appears 
to be directly proportional to ventricular volume expan-
sion and pressure overload.
15) BNP is an independent 
predictor of high LV end-diastolic pressure and the NT-
proBNP levels were positively correlated with the NYHA 
functional class of dyspnea and the systolic dysfunc-
tion.
16)17) The measurement of NT-proBNP has been 
reported to be a non-invasive, simple, and accurate test 
for older patients, obese patients, patients with chronic 
pulmonary diseases, and even for those patients having 
difficulty being tested by echocardiogram. Thus, its cli-
nical usefulness for the differential diagnosis of heart 
failure is important.
18)19) Elevated body mass index (BMI) 
and obesity have been associated with hypertension, in-
sulin resistance and recent studies demonstrated that 
obesity is associated with decreased levels of NT-proBNP 
and raised concerns about the diagnostic and prognos-
tic validity of natriuretic peptides in obese patients.
11)20) 
Several potential mechanistic explanations deserve con-
sideration. First, it is possible that the low natriuretic 
peptide levels in overweight and obese patients reflect 
less advanced stages of HF compared with lean patients.
21) 
Cardiac cachexia, a state characterized by weight loss and 
neurohumoral/cytokine activation, is another potential 
explanation for a low BMI-high BNP association.
22) Re-
cent evidence suggests that there may be increased clea-
rance of circulating BNP in obesity because natriuretic 
peptide clearance receptors are abundant on human adi-
pocytes.
23) High levels of BNP could, through their lipo-
lytic effect, be expected to exaggerate the wasting process, 
which implies that a reduced BNP level in obese HF 
patients may be related to a decreased level of wasting. 
Conversely, it is also possible that overweight and obe-
sity are associated with less robust synthesis and/or re-
lease of BNP from the myocardium.
5) In the present study, 
NT-proBNP concentrations were lower in obese non 
DM patients despite higher E/Ea which has been shown 
to correlate with invasive measures of LV filling pres-
sure
24) and this occurs with presence of myocardial is-
chemia confirmed by coronary angiography. These find-
ings have several implications. Not only do they bring 
into question the proper use of NT-proBNP as diagno-
Fig. 2. Drop-line charts of mean log NT-proBNP showing differences in the presence of significant coronary artery disease (CAD). Con-
centrations decrease with increasing obesity, which is statistically significant in non-DM patients (p=0.002). NT-pro BNP: amino-terminal
pro-brain natriuretic peptide, DM: diabetes mellitus.   
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stic tests for obese patients with volume overload, but 
they also raise the possibility that the decreased con-
centrations of natriuretic peptides may play a role in the 
development of heart failure in obese patients. However, 
the present study demonstrates that NT-proBNP is not 
suppressed in obese patients with DM and also shows a 
poor correlation with E/Ea. The mechanisms of NT-
pro BNP is not suppressed in obese patients with diabetes 
can be explained by several possibilities. The natriuretic 
system and adiposity are closely linked bidirectionally.
25) 
Lipolysis is mediated by catecholamines (stimulation of 
lipolysis) and insulin (inhibition of lipolysis), and na-
triuretic peptides have recently been shown to be im-
portant stimuli for lipolysis in humans and are similar 
in potency to catecholamines, and their effect is in-
dependent of both catecholamines and an insulin pa-
thway.
26) So, obese diabetic patients may have higher con-
centrations of natriuretic peptides compared with those 
without diabetes. Moreover, DM patients may be more 
likely to excrete NT-proBNP (and BNP) in response to a 
similar degree of ischemic insult,
27) and then the higher 
NT-proBNP concentrations that we observed in patients 
with DM in the absence of overt HF, a finding consi-
dered to represent a “summation effect” of risk factors 
for structural heart disease, may still indicate an increas-
ed risk for cardiovascular morbidity and mortality. 
Our present study is meaningful as we obtained the 
basic clinical data on the NT-proBNP test from a large 
study population. However, as our study was a cross-sec-
tion study and the study population was not homoge-
nous, further prospective study will be required. In ad-
dition, although the accuracy of the test was high, in 
some patients, their clinical results did not correlate to 
the NT-proBNP value. In the interpretation of the NT-
proBNP test, therefore, clinical results and echocardio-
graphy must also be taken into consideration. Third, the 
patients with renal insufficiency were also excluded in 
the present study. Because, in the setting of HF, impair-
ed renal function is common and strongly related with 
adverse outcomes, further study is warranted that will 
investigate the relationship between obesity and plasma 
BNP under the condition of renal insufficiency. Further 
studies will be required on patients showing a discrepancy 
between clinical features and symptoms and the NT-
proBNP values.   
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